MIS416 is a new experimental medication in clinical trial studies for secondary progressive multiple sclerosis. MIS416 is microparticle derived from bacteria, combined with two immune-modifying molecules. It acts to stimulate a specific range of responses in the immune system.
|This item is relevant to you: Multiple sclerosis||1||0||
- Can't tell
Currently using MS Phase 2B Study MIS416
|This item is relevant to you: 2 - 5 years||1||